Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)
Taiwan · Delayed Price · Currency is TWD 31.90
+0.10 (0.31%)
Jul 23, 2025, 1:30 PM CST
TPEX:4111 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,218 | 1,165 | 1,061 | 1,143 | 1,022 | 979.36 | Upgrade | |
Revenue Growth (YoY) | 14.36% | 9.86% | -7.19% | 11.81% | 4.38% | -4.26% | Upgrade |
Cost of Revenue | 780.37 | 768.25 | 717.76 | 720.57 | 665.72 | 656.44 | Upgrade |
Gross Profit | 437.47 | 397.18 | 343.1 | 422.51 | 356.58 | 322.92 | Upgrade |
Selling, General & Admin | 289.72 | 280.24 | 260.22 | 248.99 | 218.59 | 229.15 | Upgrade |
Research & Development | 16.96 | 18 | 21.67 | 19.69 | 18.94 | 18.21 | Upgrade |
Operating Expenses | 306.68 | 298.25 | 281.89 | 268.67 | 237.52 | 247.37 | Upgrade |
Operating Income | 130.79 | 98.93 | 61.21 | 153.84 | 119.06 | 75.55 | Upgrade |
Interest Expense | -1.37 | -1.74 | -1.46 | -1.53 | -1.09 | -0.16 | Upgrade |
Interest & Investment Income | 12.7 | 14.58 | 16.64 | 3 | 0.6 | 1.99 | Upgrade |
Currency Exchange Gain (Loss) | 7.51 | 17.08 | -0.43 | 4.72 | -1.76 | -3.25 | Upgrade |
Other Non Operating Income (Expenses) | 11.55 | 11.22 | 11.5 | 7.21 | 8.06 | 7.09 | Upgrade |
EBT Excluding Unusual Items | 161.18 | 140.08 | 87.46 | 167.24 | 124.86 | 81.22 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -5.03 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -2.57 | -2.38 | -0.13 | 0.07 | 0.12 | 0.2 | Upgrade |
Asset Writedown | - | - | - | - | 6.8 | - | Upgrade |
Other Unusual Items | - | - | 0 | - | - | - | Upgrade |
Pretax Income | 158.61 | 137.7 | 87.33 | 162.28 | 131.78 | 81.43 | Upgrade |
Income Tax Expense | 32.35 | 27.07 | 18.66 | -17 | 24.08 | 22.28 | Upgrade |
Earnings From Continuing Operations | 126.26 | 110.63 | 68.67 | 179.28 | 107.7 | 59.14 | Upgrade |
Earnings From Discontinued Operations | - | - | - | -25.28 | -26.95 | - | Upgrade |
Net Income | 126.26 | 110.63 | 68.67 | 154.01 | 80.75 | 59.14 | Upgrade |
Net Income to Common | 126.26 | 110.63 | 68.67 | 154.01 | 80.75 | 59.14 | Upgrade |
Net Income Growth | 72.76% | 61.10% | -55.41% | 90.72% | 36.54% | -18.37% | Upgrade |
Shares Outstanding (Basic) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade |
Shares Outstanding (Diluted) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade |
Shares Change (YoY) | 0.21% | 0.12% | -0.16% | 0.06% | 0.10% | -0.01% | Upgrade |
EPS (Basic) | 2.22 | 1.94 | 1.21 | 2.70 | 1.42 | 1.04 | Upgrade |
EPS (Diluted) | 2.21 | 1.93 | 1.20 | 2.69 | 1.41 | 1.03 | Upgrade |
EPS Growth | 74.00% | 60.83% | -55.37% | 90.77% | 36.85% | -18.90% | Upgrade |
Free Cash Flow | 128.3 | 129.01 | -26.98 | 109.53 | -125.53 | 121.53 | Upgrade |
Free Cash Flow Per Share | 2.24 | 2.25 | -0.47 | 1.91 | -2.19 | 2.12 | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.200 | 1.000 | 1.000 | Upgrade |
Dividend Growth | - | - | -16.67% | 20.00% | - | - | Upgrade |
Gross Margin | 35.92% | 34.08% | 32.34% | 36.96% | 34.88% | 32.97% | Upgrade |
Operating Margin | 10.74% | 8.49% | 5.77% | 13.46% | 11.65% | 7.71% | Upgrade |
Profit Margin | 10.37% | 9.49% | 6.47% | 13.47% | 7.90% | 6.04% | Upgrade |
Free Cash Flow Margin | 10.54% | 11.07% | -2.54% | 9.58% | -12.28% | 12.41% | Upgrade |
EBITDA | 196.7 | 165.23 | 123.17 | 219.2 | 190.95 | 152.45 | Upgrade |
EBITDA Margin | 16.15% | 14.18% | 11.61% | 19.18% | 18.68% | 15.57% | Upgrade |
D&A For EBITDA | 65.91 | 66.3 | 61.96 | 65.36 | 71.9 | 76.9 | Upgrade |
EBIT | 130.79 | 98.93 | 61.21 | 153.84 | 119.06 | 75.55 | Upgrade |
EBIT Margin | 10.74% | 8.49% | 5.77% | 13.46% | 11.65% | 7.71% | Upgrade |
Effective Tax Rate | 20.39% | 19.66% | 21.36% | - | 18.27% | 27.37% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.